15-May-2026
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Globe Newswire (Thu, 7-May 7:00 AM ET)
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 5-May 4:01 PM ET)
Globe Newswire (Mon, 20-Apr 7:00 AM ET)
Globe Newswire (Tue, 17-Mar 7:00 AM ET)
Market Chameleon (Mon, 16-Mar 4:40 AM ET)
Globe Newswire (Mon, 16-Mar 7:00 AM ET)
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 23-Feb 7:00 AM ET)
GLUE’s $200 Million Public Offering Proposal Spotlights Bold Expansion Strategy
Market Chameleon (Thu, 8-Jan 6:55 AM ET)
GLUE’s MRT-8102 Shows 85% Reduction in Inflammatory Marker—Data Points to Broad Impact in CVD
Market Chameleon (Wed, 7-Jan 2:05 AM ET)
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Monte Rosa Therapeutics trades on the NASDAQ stock market under the symbol GLUE.
As of May 15, 2026, GLUE stock price declined to $18.15 with 880,719 million shares trading.
GLUE has a beta of 1.25, meaning it tends to be more sensitive to market movements. GLUE has a correlation of 0.04 to the broad based SPY ETF.
GLUE has a market cap of $1.53 billion. This is considered a Small Cap stock.
Last quarter Monte Rosa Therapeutics reported $4 million in Revenue and -$.45 earnings per share. This fell short of revenue expectation by $-9 million and missed earnings estimates by -$.09.
In the last 3 years, GLUE traded as high as $25.77 and as low as $2.44.
The top ETF exchange traded funds that GLUE belongs to (by Net Assets): XBI, VTI, AVUV, IWM, VXF.
GLUE has outperformed the market in the last year with a return of +369.0%, while the SPY ETF gained +26.4%. However, in the most recent history, GLUE shares have underperformed the stock market with its stock returning +1.3% in the last 3 month period and -3.5% for the last 2 week period, while SPY has returned +8.7% and +2.6%, respectively.
GLUE support price is $18.01 and resistance is $19.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLUE shares will trade within this expected range on the day.
